C61
Conditions
Interventions
Group 1: Study protocol MRI (3.0 Tesla):
1. Localizer sequence to plan scan orientations
2. high-resolution T2-weighted images in sagittal, coronal and axial orientation
3. diffusion-weighted (DWI) im
Sponsors
Universitätsklinikum Freiburg
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Male patients older than 18 years, with histologically confirmed prostate cancer. - Where the biopsy at the time of the first MR examination at least 6 weeks is back - The radiation therapy can be obtained as primary therapy (5 x 2 Gy / week up to a total dose of 72-76 Gy) - Have no restriction on the kidney function. - No contraindications for the whole-body MRI - Consent to participate in the study after detailed explanation of previous and written consent
Exclusion criteria
Exclusion criteria: - TURP prior to study inclusion - Pre-irradiation in the pelvic area - Start an anti-hormonal therapy prior to study entry - Contraindications to MR studies (pacemakers, metallic clips after magnetizable brain or heart surgery, cochlear implants, metallic foreign body in the eye, insulin pumps, etc.). - Ferromagnetic intracorporeal debris - SM / AICD implantation - Lack of written informed consent - Combined radiation therapy (HDR afterloading percutaneous) - Severe allergic diathesis - Known allergy to contrast agent gadolinium-chelates - Renal (filtration rate <40 ml / min) - prior kidney and liver transplant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Based on MRI to quantitative parameters (relaxation times, "Apparent" diffusion coefficient and perfusion) are determined before and after radiotherapy of prostate cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| A correlation between changes in MRI parameters and the PSA level can be checked further. | — |
Countries
Germany
Contacts
Public ContactHans Christian Rischke
Universitätsklinikum Freiburg
Outcome results
None listed